Efficacy of Combined Contraceptive Vaginal Ring Versus Oral Contraceptive Pills in Achieving Hypothalamic-Pituitary-Ovarian Axis Suppression in Egg Donor In Vitro Fertilization Cycles
نویسندگان
چکیده
BACKGROUND Our study compares the efficacy of the combined contraceptive vaginal ring to oral contraceptive pills (OCPs) for hypothalamic-pituitary-ovarian (HPO) axis suppression in egg donor in vitro fertilization (IVF) cycles. METHODS Our retrospective cohort study includes patients from the Center for Assisted Reproduction (CARE) in Bedford, Texas undergoing IVF cycles as egg donors from January 2003 through December 2009. Twenty-five and thirty-nine women were treated with OCPs and the combined contraceptive vaginal ring, respectively. Statistical analyses were performed using the SigmaStat Software package (Systat, Chicago, IL). Data were analyzed by t or Mann-whitney test and Chi-square of Fisher exact test. Statistical significance was set at p<0.05. RESULTS Prior to gonadotropin initiation, endometrial thickness and serum estradiol were 5.6±2.6 mm and 33.6±19.9 pg/ml in the OCP group and 6.0±2.4 mm and 36.6±24.3 pg/ml in the combined contraceptive vaginal ring group, respectively (p=0.49 and p=0.33). Average serum FSH and LH were 1.7±1.9 and 1.7±2.5 mIU/ml in the OCP group and 1.7±1.6 and 1.2±1.4 mIU/ml in the combined contraceptive vaginal ring group, respectively (p=0.45 and p=0.95). No significant differences were found for gonadotropin requirement, peak estradiol, maximal endometrial thickness, number of oocytes retrieved, number of normally fertilized embryos, number of cryopreserved embryos, or live birth rates. CONCLUSION The combined contraceptive vaginal ring is effective for HPO axis suppression in egg donor IVF cycles and associated with cycle characteristics similar to those observed with OCP treatment. The combined contraceptive vaginal ring may provide an important advantage over OCPs due to improved patient compliance.
منابع مشابه
Unintended Pregnancy with Implantable Subdermal Contraceptive Device (Nexplanon): A Case Report
Implanon, an Etonogestrel capsule, containing 68 mg of the synthetic progestin etonogestrel implant, was first introduced in Indonesia in 1998 and approved for use in the U.S. in 2006, as a subcutaneous hormone eluting capsule providing longacting reversible contraception (LARC) [1-4]. Prior to the use of Implanon, short-acting reversible contraceptives (SARC) such as oral contraceptive pills (...
متن کاملEVALUATION OF SIDE EFFECTS OF LOW DOSE CONTRACEPTIV E PILLS ADMINISTERED BY THE VAGINAL ROUTE
Oral contraceptive pills have several side effects especially on the gastrointestinal tract and liver. Absorption of low dose (LD) pills by the vaginal route avoids the first pass of the steroids through these tracts and probably has fewer side effects. This study was a cohort study for evaluation of side effects and acceptability of LD pills administered by the vaginal route. In a clinical...
متن کاملResidual ovarian activity during oral steroid contraception.
Steroid drugs with contraceptive properties have been available in the clinical setting for over four decades and are still subject to improvement. Estrogens, progestins and anti-progestins have been used alone or in various combinations, regimens and routes of administration to favour the balance between efficacy and undesirable effects. One of the most important changes in this respect is the...
متن کاملEstradiol Valerate Pretreatment in Short Protocol GnRH-Agonist Cycles versus Combined Pretreatment with Oral Contraceptive Pills in Long Protocol GnRH-Agonist Cycles: A Randomised Controlled Trial
The strategy of in vitro fertilization (IVF) procedures relies on the increasing pregnancy rate and decreasing the risk of premature ovulation and ovarian hyperstimulation syndrome. They are also designed to avoid weekend oocyte retrievals. Combined oral contraceptive (OC) pills are among the medicines used to accomplish these objectives. Alternatively, estradiol can be used instead of OC to ob...
متن کاملExtended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling
BACKGROUND Contraceptive implants, the levonorgestrel-releasing intrauterine system (LNG IUS), and the copperbearing intrauterine device (IUD) are long-acting reversible contraceptives (LARCs) with high contraceptive effectiveness. The cumulative pregnancy rates in the first 3 years of use of LARCs is 0.9 per 100 woman-years. In comparison, the percentages of women experiencing an unintended pr...
متن کامل